Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

Sponsor
Sichuan University
Study ID
NCT07067346
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Months - N/A
Healthy Volunteers
Not accepted

Interventions

  • IR-101 — DRUG
    IR-101 Dose Escalation

Study Details

Radiopharmaceutical in Relapsed/Refractory Neuroblastoma

Key Dates

Start date
Jul 18, 2025
Status verified
Jul 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation
    Study drug IR-101 Dose Escalation

Primary Outcome Measure

Incidence and severity of dose-limiting toxicities (DLTs) [ Time Frame: From administration of IR-101 until 4 weeks after injection ]

Central Contacts

Related Studies